Desloratadin hatékonyságának és tolerálhatóságának multicentrikus vizsgálata szezonális allergiás rhinitisben.

Translated title of the contribution: Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

INTRODUCTION: The authors appraised the clinical efficacy of desloratadine in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted on 428 patients between 3 June and 31 July 2002 in 11 centres. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular clinical signs were characterized using a symptom score. Desloratadine tablet was administered in 5 mg doses. After two weeks of treatment, the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Desloratadine significantly alleviated all four nasal symptoms and ocular effectively. In particular, treatment resulted from 76 percent to 12% percent decrease of overall symptom score. One of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that desloratidine is a safe and effective systemic antihistamine--with complex antiallergic effect--for the therapy of seasonal allergic rhinitis and rhinoconjunctivitis. It can reduce nasal congestion with greater magnitude than other known antihistamines.

Original languageHungarian
Pages (from-to)1021-1024
Number of pages4
JournalOrvosi Hetilap
Volume144
Issue number21
Publication statusPublished - May 25 2003

Fingerprint

Seasonal Allergic Rhinitis
Multicenter Studies
Histamine Antagonists
Nose
Sneezing
Therapeutics
Anti-Allergic Agents
Nasal Obstruction
Pruritus
Tablets
desloratadine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Desloratadin hatékonyságának és tolerálhatóságának multicentrikus vizsgálata szezonális allergiás rhinitisben. / Farkas, H.

In: Orvosi Hetilap, Vol. 144, No. 21, 25.05.2003, p. 1021-1024.

Research output: Contribution to journalArticle

@article{abe61cc2058f417aa44a90f4421eceea,
title = "Desloratadin hat{\'e}konys{\'a}g{\'a}nak {\'e}s toler{\'a}lhat{\'o}s{\'a}g{\'a}nak multicentrikus vizsg{\'a}lata szezon{\'a}lis allergi{\'a}s rhinitisben.",
abstract = "INTRODUCTION: The authors appraised the clinical efficacy of desloratadine in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted on 428 patients between 3 June and 31 July 2002 in 11 centres. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular clinical signs were characterized using a symptom score. Desloratadine tablet was administered in 5 mg doses. After two weeks of treatment, the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Desloratadine significantly alleviated all four nasal symptoms and ocular effectively. In particular, treatment resulted from 76 percent to 12{\%} percent decrease of overall symptom score. One of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that desloratidine is a safe and effective systemic antihistamine--with complex antiallergic effect--for the therapy of seasonal allergic rhinitis and rhinoconjunctivitis. It can reduce nasal congestion with greater magnitude than other known antihistamines.",
author = "H. Farkas",
year = "2003",
month = "5",
day = "25",
language = "Hungarian",
volume = "144",
pages = "1021--1024",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "21",

}

TY - JOUR

T1 - Desloratadin hatékonyságának és tolerálhatóságának multicentrikus vizsgálata szezonális allergiás rhinitisben.

AU - Farkas, H.

PY - 2003/5/25

Y1 - 2003/5/25

N2 - INTRODUCTION: The authors appraised the clinical efficacy of desloratadine in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted on 428 patients between 3 June and 31 July 2002 in 11 centres. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular clinical signs were characterized using a symptom score. Desloratadine tablet was administered in 5 mg doses. After two weeks of treatment, the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Desloratadine significantly alleviated all four nasal symptoms and ocular effectively. In particular, treatment resulted from 76 percent to 12% percent decrease of overall symptom score. One of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that desloratidine is a safe and effective systemic antihistamine--with complex antiallergic effect--for the therapy of seasonal allergic rhinitis and rhinoconjunctivitis. It can reduce nasal congestion with greater magnitude than other known antihistamines.

AB - INTRODUCTION: The authors appraised the clinical efficacy of desloratadine in patients with seasonal allergic rhinitis and rhinoconjunctivitis. PATIENTS AND METHODS: An open, two-week trial was conducted on 428 patients between 3 June and 31 July 2002 in 11 centres. Nasal obstruction, rhinorrhea, sneezing, and itching as well as ocular clinical signs were characterized using a symptom score. Desloratadine tablet was administered in 5 mg doses. After two weeks of treatment, the symptom score was re-evaluated. Potential adverse events that had occurred during the treatment period were recorded. RESULTS: Desloratadine significantly alleviated all four nasal symptoms and ocular effectively. In particular, treatment resulted from 76 percent to 12% percent decrease of overall symptom score. One of the participants discontinued treatment due to the occurrence of adverse effects. CONCLUSION: These results demonstrate that desloratidine is a safe and effective systemic antihistamine--with complex antiallergic effect--for the therapy of seasonal allergic rhinitis and rhinoconjunctivitis. It can reduce nasal congestion with greater magnitude than other known antihistamines.

UR - http://www.scopus.com/inward/record.url?scp=0042202316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042202316&partnerID=8YFLogxK

M3 - Article

C2 - 12847854

AN - SCOPUS:0042202316

VL - 144

SP - 1021

EP - 1024

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 21

ER -